Drugs.com - New Drug Approvals

FDA Approves Yesintek (ustekinumab-kfce), a Biosimilar to Stelara

Bengaluru, Karnataka, India, December 01, 2024 -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the U.S. Food and Drug Administration...

Feb 9, 2025 - 22:25
 0
FDA Approves Yesintek (ustekinumab-kfce), a Biosimilar to Stelara
Bengaluru, Karnataka, India, December 01, 2024 -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the U.S. Food and Drug Administration...
Read More

Tags:

Previous Article

FDA Grants Accelerated Approval to Bizengri (zenocutuzumab-zbco) for NRG1+ Pancr...

Next Article

FDA Approves Rapiblyk (landiolol) for Atrial Fibrillation and Atrial Flutter in ...

Related Posts

FDA Approves Zepbound (tirzepatide) as the First and Only Prescription Medicine for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity

FDA Approves Zepbound (tirzepatide) as the First and On...

Feb 9, 2025  0

FDA Approves Ctexli (chenodiol) for Cerebrotendinous Xanthomatosis

FDA Approves Ctexli (chenodiol) for Cerebrotendinous Xa...

Feb 24, 2025  0

FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Treatment of Diabetic Macular Edema

FDA Approves Genentech’s Susvimo as the First and Only ...

Feb 9, 2025  0